Roche (RHHBY.US) submitted a PD-L1 inhibitor subcutaneous injection for marketing approval in China.

On July 27, the China National Medical Products Administration (NMPA) published on its website that the marketing application of Roche's (RHHBY.US) anti-PD-L1 monoclonal antibody (subcutaneous injection) has been accepted. According to the public information, the subcutaneous injection type of the product has been approved in many indications globally. The subcutaneous injection of atezolizumab can shorten the treatment time of each injection to 4-8 minutes (usually 7 minutes), while the standard intravenous infusion needs 30-60 minutes.

Atezolizumab (Tecentriq) is a monoclonal antibody targeting PD-L1 developed by Roche. It has been approved globally for the treatment of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), urothelial carcinoma, metastatic triple-negative breast cancer (mTNBC) and multiple advanced solid tumors with BRAF V600 mutation. It has been approved for the treatment of extensive-stage small cell lung cancer in China in 2020.